Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction?

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction? / Scott, Susanne I; Andersen, Michelle F; Aagaard, Lise; Buchwald, Christian Von; Rasmussen, Eva R.

I: Current Diabetes Reviews, Bind 14, Nr. 4, 2018, s. 327-333.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Scott, SI, Andersen, MF, Aagaard, L, Buchwald, CV & Rasmussen, ER 2018, 'Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction?', Current Diabetes Reviews, bind 14, nr. 4, s. 327-333. https://doi.org/10.2174/1573399813666170214113856

APA

Scott, S. I., Andersen, M. F., Aagaard, L., Buchwald, C. V., & Rasmussen, E. R. (2018). Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction? Current Diabetes Reviews, 14(4), 327-333. https://doi.org/10.2174/1573399813666170214113856

Vancouver

Scott SI, Andersen MF, Aagaard L, Buchwald CV, Rasmussen ER. Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction? Current Diabetes Reviews. 2018;14(4):327-333. https://doi.org/10.2174/1573399813666170214113856

Author

Scott, Susanne I ; Andersen, Michelle F ; Aagaard, Lise ; Buchwald, Christian Von ; Rasmussen, Eva R. / Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction?. I: Current Diabetes Reviews. 2018 ; Bind 14, Nr. 4. s. 327-333.

Bibtex

@article{6eb4920c88a842fca2ac7ac4a4e167c9,
title = "Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction?",
abstract = "INTRODUCTION: Angioedema is a potentially fatal adverse drug reaction of some medications, as swellings of the upper airways can cause death by asphyxiation. Angiotensin converting enzymeinhibitors are widely known to cause angioedema but less is known about the association between dipeptidyl peptidase-4 inhibitors (gliptins) and angioedema. Dipeptidyl peptidase-4 inhibitors are antidiabetic drugs used to improve glycaemic control. They, as a class effect, inadvertently affect the degradation of the vasoactive kinins bradykinin and substance P, both of which can cause angioedema due to vasodilatation and increase in vascular permeability in the capillaries.OBJECTIVE: To assess the risk and pathomechanism of angioedema due to inhibition of dipeptidyl peptidase- 4 inhibitors when used as monotherapy and in combination with angiotensin converting enzymeinhibitors.METHOD: PubMed, Embase, the Cochrane Library, PubMed Central, Web of Science, Google Scholar and clinicaltrials.gov were searched using different combinations of keywords {"}angioedema{"}, {"}dipeptidyl peptidase 4{"}, {"}dipeptidyl peptidase 4 inhibitors{"}, {"}gliptins{"}, {"}bradykinin{"}, {"}substance P{"} and {"}angiotensin converting enzyme-inhibitors{"}. Original research papers were preferably used as references and their bibliographies were used to further the search for original research results.RESULTS: Both angiotensin converting enzyme and dipeptidyl peptidase-4 are major enzymes in the degradation pathway of bradykinin and substance P, and when inhibited pharmacologically - especially at the same time - the theoretical risk of angioedema is increased due to accumulation of vasoactive kinins.CONCLUSION: Treatment with dipeptidyl peptidase-4 inhibitors must be carefully considered and monitored especially during concurrent treatment with angiotensin converting enzyme-inhibitors or when treating patients with a known predisposition to angioedema.",
keywords = "Angioedema/chemically induced, Angiotensin-Converting Enzyme Inhibitors/adverse effects, Animals, Bradykinin/metabolism, Capillary Permeability, Dipeptidyl Peptidase 4/metabolism, Dipeptidyl-Peptidase IV Inhibitors/adverse effects, Drug Interactions, Genetic Predisposition to Disease, Humans, Prognosis, Proteolysis, Risk Factors, Substance P/metabolism, Vasodilation",
author = "Scott, {Susanne I} and Andersen, {Michelle F} and Lise Aagaard and Buchwald, {Christian Von} and Rasmussen, {Eva R}",
note = "Copyright{\textcopyright} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2018",
doi = "10.2174/1573399813666170214113856",
language = "English",
volume = "14",
pages = "327--333",
journal = "Current Diabetes Reviews",
issn = "1573-3998",
publisher = "Bentham Science Publishers",
number = "4",

}

RIS

TY - JOUR

T1 - Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction?

AU - Scott, Susanne I

AU - Andersen, Michelle F

AU - Aagaard, Lise

AU - Buchwald, Christian Von

AU - Rasmussen, Eva R

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2018

Y1 - 2018

N2 - INTRODUCTION: Angioedema is a potentially fatal adverse drug reaction of some medications, as swellings of the upper airways can cause death by asphyxiation. Angiotensin converting enzymeinhibitors are widely known to cause angioedema but less is known about the association between dipeptidyl peptidase-4 inhibitors (gliptins) and angioedema. Dipeptidyl peptidase-4 inhibitors are antidiabetic drugs used to improve glycaemic control. They, as a class effect, inadvertently affect the degradation of the vasoactive kinins bradykinin and substance P, both of which can cause angioedema due to vasodilatation and increase in vascular permeability in the capillaries.OBJECTIVE: To assess the risk and pathomechanism of angioedema due to inhibition of dipeptidyl peptidase- 4 inhibitors when used as monotherapy and in combination with angiotensin converting enzymeinhibitors.METHOD: PubMed, Embase, the Cochrane Library, PubMed Central, Web of Science, Google Scholar and clinicaltrials.gov were searched using different combinations of keywords "angioedema", "dipeptidyl peptidase 4", "dipeptidyl peptidase 4 inhibitors", "gliptins", "bradykinin", "substance P" and "angiotensin converting enzyme-inhibitors". Original research papers were preferably used as references and their bibliographies were used to further the search for original research results.RESULTS: Both angiotensin converting enzyme and dipeptidyl peptidase-4 are major enzymes in the degradation pathway of bradykinin and substance P, and when inhibited pharmacologically - especially at the same time - the theoretical risk of angioedema is increased due to accumulation of vasoactive kinins.CONCLUSION: Treatment with dipeptidyl peptidase-4 inhibitors must be carefully considered and monitored especially during concurrent treatment with angiotensin converting enzyme-inhibitors or when treating patients with a known predisposition to angioedema.

AB - INTRODUCTION: Angioedema is a potentially fatal adverse drug reaction of some medications, as swellings of the upper airways can cause death by asphyxiation. Angiotensin converting enzymeinhibitors are widely known to cause angioedema but less is known about the association between dipeptidyl peptidase-4 inhibitors (gliptins) and angioedema. Dipeptidyl peptidase-4 inhibitors are antidiabetic drugs used to improve glycaemic control. They, as a class effect, inadvertently affect the degradation of the vasoactive kinins bradykinin and substance P, both of which can cause angioedema due to vasodilatation and increase in vascular permeability in the capillaries.OBJECTIVE: To assess the risk and pathomechanism of angioedema due to inhibition of dipeptidyl peptidase- 4 inhibitors when used as monotherapy and in combination with angiotensin converting enzymeinhibitors.METHOD: PubMed, Embase, the Cochrane Library, PubMed Central, Web of Science, Google Scholar and clinicaltrials.gov were searched using different combinations of keywords "angioedema", "dipeptidyl peptidase 4", "dipeptidyl peptidase 4 inhibitors", "gliptins", "bradykinin", "substance P" and "angiotensin converting enzyme-inhibitors". Original research papers were preferably used as references and their bibliographies were used to further the search for original research results.RESULTS: Both angiotensin converting enzyme and dipeptidyl peptidase-4 are major enzymes in the degradation pathway of bradykinin and substance P, and when inhibited pharmacologically - especially at the same time - the theoretical risk of angioedema is increased due to accumulation of vasoactive kinins.CONCLUSION: Treatment with dipeptidyl peptidase-4 inhibitors must be carefully considered and monitored especially during concurrent treatment with angiotensin converting enzyme-inhibitors or when treating patients with a known predisposition to angioedema.

KW - Angioedema/chemically induced

KW - Angiotensin-Converting Enzyme Inhibitors/adverse effects

KW - Animals

KW - Bradykinin/metabolism

KW - Capillary Permeability

KW - Dipeptidyl Peptidase 4/metabolism

KW - Dipeptidyl-Peptidase IV Inhibitors/adverse effects

KW - Drug Interactions

KW - Genetic Predisposition to Disease

KW - Humans

KW - Prognosis

KW - Proteolysis

KW - Risk Factors

KW - Substance P/metabolism

KW - Vasodilation

U2 - 10.2174/1573399813666170214113856

DO - 10.2174/1573399813666170214113856

M3 - Review

C2 - 28201967

VL - 14

SP - 327

EP - 333

JO - Current Diabetes Reviews

JF - Current Diabetes Reviews

SN - 1573-3998

IS - 4

ER -

ID: 216565132